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Background: MiR-221 is over-expressed in human hepatocellular carcinoma (HCC), but its clinical significance and
function in HCC remains uncertain. The aim of the study was to investigate the relationship between miR-221
overexpression and clinicopathological parameters in HCC formalin-fixed paraffin-embedded (FFPE) tissues, and the
effect of miR-221 inhibitor and mimic on different HCC cell lines in vitro.
Methods: MiR-221 expression was detected using real time RT-qPCR in FFPE HCC and the adjacent noncancerous
liver tissues. The relationship between miR-221 level and clinicopathological features was also analyzed.
Furthermore, miR-221 inhibitor and mimic were transfected into HCC cell lines HepB3, HepG2 and SNU449. The
effects of miR-221 on cell growth, cell cycle, caspase activity and apoptosis were also investigated by
spectrophotometry, fluorimetry, fluorescence microscopy and flow cytometry, respectively.
Results: The relative expression of miR-221 in clinical TNM stages III and IV was significantly higher than that in the
stages I and II. The miR-221 level was also upregulated in the metastatic group compared to the nonmetastatic
group. Furthermore, miR-221 over-expression was related to the status of tumor capsular infiltration in HCC clinical
samples. Functionally, cell growth was inhibited, cell cycle was arrested in G1/S-phase and apoptosis was increased
by miR-221 inhibitor in vitro. Likewise, miR-221 mimic accelerated the cell growth.
Conclusions: Expression of miR-221 in FFPE tissues could provide predictive significance for prognosis of HCC
patients. Moreover, miR-221 inhibitor could be useful to suppress proliferation and induce apoptosis in HCC cells.
Thus miR-221 might be a critical targeted therapy strategy for HCC.
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Primary liver cancer includes hepatocellular carcinoma
(HCC), intrahepatic cholangiocarcinoma (ICC), and hepatic
angiosarcoma. As the third leading cause of death from
cancer (an estimated 549,000 deaths per year), HCC
accounts for 85–90% of all primary liver cancers and ranks
as the fifth most prevalent malignancy all over the world
[1-4]. The development and progression of HCC is typical
of a multistage process. It has been well documented that
infection with hepatitis B and C virus (HBV and HCV) is* Correspondence: tourtair@163.com
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reproduction in any medium, provided the orthe major etiological factor for the development of HCC
[1-3,5,6]. The progression is considered to involve the
deregulation of genes that are critical to cellular processes
such as cell cycle control, apoptosis, cell migration and
invasion. Many reports have highlighted on investigating
genes and proteins underlying the development and pro-
gression of HCC, however, their sensitivity and specificity
are limited [7-14]. Therefore, the identification of new
biomarkers is urgently needed in order to understand the
events causing hepatocarcinogenesis, also to relate various
phenotypes in clinical features and prognosis and,
more importantly, to predict response possibilities to
therapeutic approaches.
The current therapies for HCC remain also challenging.
At the earliest stages, HCC is treatable by resection ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 MiR-221 relative expression in HCC FFPE samples.
MiR-221 levels accessed by real time RT-qPCR in HCCs and their adjacent
noncancerous liver tissues. N: noncancerous liver tissues. ** P<0.01.
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in patients who are afflicted with early HCC and not
suitable for resection or transplantation [15,16].
Transarterial chemoembolization has been effectively
utilized in patients with HCC of intermediate stage
[17]. Patients with advanced disease or whose cancer
recurs following regional therapy have a dismal
prognosis. New molecular therapies for HCC include
epidermal growth factor receptor (EGFR) inhibitors,
for instance, erlotinib [18] and antiangiogenic com-
pounds, such as bevacizumab [19,20] and sunitinib
[21]. In a phase III trial, patients with advanced
HCC treated with the molecular targeted agent sora-
fenib, reported an increase in survival of approxi-
mately 3 months [22-25]. Nevertheless, new agents
must be developed to treat advanced HCC.
In recent years, microRNAs (miRNAs) have received
great attention in cancer research. These small, non-
coding RNAs can inhibit target gene expression by
binding to the 3’-untranslated region (3’-UTR) of
target mRNA, resulting in either mRNA degradation
or inhibition of translation to protein. MiRNAs play
essential roles in many normal biological processes
involving cell proliferation, differentiation, apoptosis,
and stress resistance [26,27]. Studies have also shown
that aberrant miRNA expression is correlated with
the development and progression of cancer, thus
miRNAs could be used as biomarkers for diagnosis
and prognosis of cancer. On the other hand, the
miRNAs can have oncogenic or tumor suppressor
activities, so miRNAs are emerging as targets for
cancer molecular therapy [28].
Extensive profiling studies over the past several
years have shown that various miRNAs are differen-
tially expressed in HCC and other types of cancers
[29-41]. Nevertheless, there is still a lot remaining to
be understood in the involvement of miRNAs in
hepatocarcinogenesis and progression of HCC. Among all
the HCC-related miRNAs, miR-221 was reported to be
increasingly expressed in HCC, compared with nondi-
seased and adjacent benign liver tissues [37,40,42-47].
However, the relationship between the miR-221 expres-
sion and clinicopathological parameters in HCC was not
fully understood.
In the present study, we investigated the expression of
miRNA-221 in HCC and their matched adjacent non-
cancerous liver tissues in formalin-fixed paraffin-embed-
ded (FFPE) surgically resected samples. Furthermore, we
analyzed the correlation between miR-221 level and
different clinicopathological parameters of HCC. We
also performed in vitro experiments to study the effect
of miR-221 on the cell growth, cell cycle, caspase-3/7
activity and apoptosis in HCC cell lines Hep3B, HepG2
and SNU449.Results
MiR-221 expression in HCC FFPE tissues and its clinical
significance
The OD260/OD280 ratio of the total mRNA isolated
from the FFPE tissues ranged from 1.84 to 2.06, and
OD260/OD230 from 1.90 to 2.04. The PCR amplifi-
cation efficiency of all the real time RT-qPCR reac-
tions ranged from 91.0% to 95.2%. The relative
expression of miR-221 in HCC tissues was signifi-
cantly higher than that of their matched adjacent
noncancerous liver tissues (P<0.05, Figure 1, Table 1).
The expression of miR-221 in clinical TNM III and
IV stages was also significantly higher than that in I
and II stages. Furthermore, in the group with metas-
tasis, miR-221 expression was upregulated compared
to the group with no metastasis (P<0.05). When
studied the relationship between miR-221 expression
and other clinicopathological parameters, we found
that miR-221 level was correlated with the status of
tumor capsular infiltration. MiR-221 level became
higher in the case that the tumors with capsular
being infiltrated by cancer cells or the tumors with
no capsular (P<0.05, Figure 2, Table 1). The miR-221
however had no correlation with other features, such
as age, gender, histological differentiation grades, cir-
rhosis, plasma AFP levels, portal vein tumor em-
bolus, number of the tumor nodes, tumor sizes or
microscopic vaso-invasion (Table 1). Forty-eight
among 76 patients were followed up and time-to-
recurrence was collected. Time-to-recurrence for all
48 cases was 28.94±3.20 weeks. The patients with
Table 1 Correlation between the expression of miR-221 and clinicopathological parameters in HCC x  sð Þ
Clinicopathological parameters n miR-221 relavant expression
2-△cq t P
Tissue HCC 76 1.86±0.39 3.46 0.001
Adjacent noncancerous liver 76 0.50±0.03
Age ≥50 35 2.73±0.79 1.965 0.057
<50 41 1.11±0.22
Gender Male 62 1.55±0.28 −0.965 0.351
Female 14 3.25±1.74
Differentiation well 4 1.68±0.86 F= 1.487 * 0.233
moderately 48 2.36±0.60
poorly 24 0.89±0.19
Clinical TNM stage I&II 20 0.65±0.09 −3.098 0.003
III&IV 56 2.29±0.52
Metastasis Yes 31 3.67±0.87 3.50 0.001
No 45 0.62±0.05
With cirrhosis Yes 40 2.01±0.66 0.402 0.689
No 36 1.69±0.40
AFP(μg/L) ≥400 30 1.84±0.81 −0.218 0.828
<400 33 2.05±0.52
Portal vein tumor embolus Yes 18 3.63±1.45 1.582 0.131
No 58 1.31±0.22
Tumor capsular infiltration no capsular or capsular infiltration 37 2.99±0.77 2.856 0.007
no capsular infiltration 39 0.79±0.08
Tumor nodes multi 34 2.47±0.81 1.285 0.206
single 42 1.37±0.26
Tumor diameter(cm) ≥5 61 1.57±0.28 −0.947 0.36
<5 14 3.24±1.75
Vaso-invasion Yes 19 3.67±1.37 1.738 0.098
No 57 1.26±0.22
* One-way Analysis of Variance (ANOVA) test was performed.
Figure 2 Relationship of miR-221 relative expression and HCC
clinicopathological features. MiR-221 levels accessed by real time
RT-qPCR in HCCs and their adjacent noncancerous liver tissues. N:
noncancerous liver tissues. I&II: clinical TNM stage I and II, III&IV:
stage III and IV. ** P<0.01.
Rong et al. BMC Cancer 2013, 13:21 Page 3 of 14
http://www.biomedcentral.com/1471-2407/13/21high expression of miR-221 (higher than the median
level) had a shorter time-to-recurrence compared to
those with low expression (24.15±3.11 vs 33.73±5.48),
however, the difference is not significant (P=0.129,
Figure 3).MiR-221 inhibitor inhibits and miR-221 mimic enhanced
cell growth in HCC cells
To exclude effects of transfection efficiency of the trans-
fection reagent on miR-221 effect, we determined HepB3
cells transfection efficiency with two approaches: cell
fluorescence by siGLO Transfection Indicators and cell
death induced by TOX Transfection Control. The trans-
fection efficiency was higher than 89% at 72 hrs and 94%
at 96 hrs, as assessed by either CellTiter-BlueW Cell
Viability Assay, or fluorescence, as assessed by fluorescence
Figure 3 Relationship between recurrence and expression of
miR-221. Forty-eight cases were followed up and the patients with
high expression of miR-221 had a shorter time-to-recurrence
compared to those with low expression.
Figure 4 Expression of CDKN1B/p27 and CDKN1C/p57 proteins
after miR-221 mimic transfection. HCC Hep3B cells were
transfected with miR-221 mimic and negative control for 96 hrs, and
the protein levels of CDKN1B/p27 and CDKN1C/p57 were performed
using western blot.
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the transfection efficiency was nearly optimal with the
current method for transfection. Transfection efficiency of
miR-221 mimic and inhibitor was further verified by RT-
qPCR assay. The miR-221 expression level decreased with
miR-221 inhibitor and increased with miR-221 mimic with
a time-dependent manner, in different degrees. After trans-
fection with the miR-221 inhibitor, the biggest ΔΔCq was
2.13 (77.15% knock-down) for HepB3, 1.32 (59.95% knock-
down) for HepG2 and SNU449 1.78 (70.88% miR-221
knock-down) 96 hrs post-transfection. After transfecting
the miR-221 mimic for 96 hrs, miR-221 levels were most
severely increased, with ΔΔCq −13.78 (14065.74 folds
upregulation) for HepB3, -12.44 (5555.65 folds upregula-
tion) for HepG2 and −11.97 (4010.71 folds upregulation)
for SNU449. Negative controls had no change of the level
of miR-221 (data not shown). Furthermore, the protein
levels of CDKN1B/p27 and CDKN1C/p57, known targets
of miR-221 [47], were examined using western blot after
different transfections. Indeed, downregulation of both
CDKN1B/p27 and CDKN1C/p57 were observed when
miR-221 mimic was transfected into HepB3 (Figure 4).
Similar results also occurred in HepG2 and SNU449 cells
(data not shown). On the contrary, an upregulation of
CDKN1B/p27 and CDKN1C/p57 proteins were also
seen after the transfection of miR-221 inhibitors (data
not shown).
We then detected the effect of miR-221 on cell viability
using a fluorimetric resorufin viability assay. With the
miR-221 inhibitor, cell viability was significantly reduced in
all cell lines tested from 48 hrs post-transfection compared
to mock controls. After transfection with the miR-221
mimic, a significant increasing in viability was noted at the48, 72 and 96 hrs in HepB3 and HepG2 compared to blank
control. In SNU449 cells, the cell viability was slightly
higher than the blank control, however, with no significant
difference (Figure 5). To verify these results, the effect on
cell proliferation was assessed using a MTS tetrazolium
assay (Figure 6), and also by microscopic counting of viable
(Hoechst 33342 positive/PI negative) cells (Figure 7,
Figure 8). In both assays the results largely mirrored the
fluorimetric resorufin viability assay results.
Cell cycle analysis was further performed with HepB3
cells transected with miR-221 mimic and inhibitor. At 96
hrs post transfection, a 1.8-fold increase in the S-phase cell
population was observed when compared to the blank
control and the negative mimic control. Meanwhile, a
concomitant decrease of the G1 phase population also
occurred (Figure 9). Likewise, cell cycle was arrested
in G1/S-phase by miR-221 inhibitor (data not shown).
MiR-221 inhibitor induces cell apoptosis in HCC cells
To verify whether miR-221 is able to influence apoptosis,
the CellTiter-Blue assay was multiplexed with a fluorescent
caspase-3/7 assay. The results showed that with the
miR-221 mimic, caspase-3/7 activity was slightly less
than the blank controls, but contained no significant
change. However, with the miR-221 inhibitor, caspase- 3/7
activity was significantly enhanced in all three HCC cell
lines tested (Figure 10). The effect on apoptosis was con-
firmed microscopically by Hoechst 33342 and PI double
Figure 5 Effect of miR-221 on cell viability of HCC cells by
CellTiter-Blue Cell Viability Assay. HCC cells were incubated in the
presence of miR-221 inhibitor, mimic and different controls for 0, 24,
48, 72 and 96 hrs, and the cell viability was measured using the
CellTiter-Blue Cell Viability Assay. * P<0.05, ** P<0.01, compared to
blank control at the same time point.
Figure 6 Effect of miR-221 on cell proliferation of HCC cells by
CellTiter96 AQueous One Solution Cell Proliferation Assay. HCC
cells were treated the same as described in Figure 5 and the cell
proliferation was measured using the MTS assay (CellTiter96
AQueous One Solution Cell Proliferation Assay). * P<0.05, ** P<0.01,
compared to blank control at the same time point.
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Figure 7 Effect of miR-221 on cell growth and apoptosis of HCC HepB3 cells by Hoechst 33342/propidium iodide (PI) double
fluorescent chromatin staining. HCC HepB3 cells were transfected with miR-221 inhibitor, mimic and different controls for 96 hrs and the cells
were observed under microscope with Hoechst 33342/PI double fluorescent chromatin staining, × 200.
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investigated the effect of miR-221 inhibitor and mimic
on HepB3 cells with 7-Amino-actinomycin D (7-AAD)/
APC Annexin V staining by flow cytometry (Figure 12).
The results from flow cytometry was also consistent with
those from caspase-3/7 assay and Hoechst 33342 and PI
double fluorescent staining, which showed that with miR-
221 inhibitor, apoptosis was induced , and on the contrary,
miR-221 mimic attenuated apoptosis.
Discussion
MiR-221 has been reported to be overexpressed in
human HCC tissues, compared with normal liver tissues
or adjacent benign liver tissues [37,40,42-48]. Four
groups studied the miR-221 expression with fresh frozen
samples using miRNA array, Northern blot or RT-qPCR
assays [44,45,47,48]. FFPE tissues were used by only two
groups to study the miR-221 expression in HCC. Fu
et al.[43] used in situ hybridization (ISH) and real time
RT-qPCR to detect the miR-221 level. Most recently,
Karakatsanis et al. [42] also investigated the miR-221 ex-
pression with real time RT-qPCR in HCC FFPE tissues.
In the current study, the result from real time RT-qPCR
in 76 cases of HCC samples confirmed the previous
reports, which showed that HCC had higher miR-221
level than other liver tissues. The overexpression of miR-
221 in HCC indicates that miR-221 plays a critical role
in the hepatocarcinogenesis, as an oncogenic miRNA.Concerning the relationship between miR-221 expres-
sion and clinicopathological parameters, several groups
reported that miR-221 level is related to the tumor
TNM stages [42,43,45]. In the present study, miR-221
expression in stage III and IV was found to be signifi-
cantly higher than that in stage I and II, which was in
line with previous reports [42,43,45]. In vivo data also
supported that miR-221 can promote tumor progression
[44]. Meanwhile, consistent with Fu et al. [43], miR-221
expression was significantly upregulated in metastatic
group compared to that in the nonmetastatic group.
Additionally, miR-221 expression was correlated with
the status of tumor capsular infiltration. In the group of
tumor capsular infiltration with cancer cells or tumor
with no capsular, miR-221 was significantly higher than
that in the group of tumor without capsular infiltration.
Generally, the status of tumor capsular infiltration
reflects tumor invasion and metastasis. Thus, the result
in current study reveals an obvious relation between
miR-221 and the infiltration of tumor cells, migration,
invasion and metastasis of HCC. The recurrence oc-
curred quicker in the patients with high expression of
miR-221 than those with low expression of miR-221.
The difference was not significant, however there was a
trend that high expression of miR-221 might lead to
HCC recurrence. Hence it may be valuable to examine
miR-221 expression for the clinical prediction of metas-
tasis of HCC. The mechanisms of miR-221 promoting
Figure 8 Effect of miR-221 on cell growth of HCC cells by
Hoechst 33342/propidium iodide (PI) double fluorescent
chromatin staining. HCC cells were treated the same as in Figure 5
and the cell growth was monitored with Hoechst 33342/PI double
fluorescent chromatin staining. * P<0.05, ** P<0.01, compared to
blank control at the same time point.
Figure 9 Effect of miR-221 on cell cycle of HCC HepB3 cells.
HCC HepB3 cells were transfected with miR-221 mimic and
negative mimic control for 96 hrs and the cell cycle was performed
with flow cytometry.
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et al. [48] showed that miR-221, by targeting PTEN and
TIMP3 tumor suppressors, induced TRAIL resistance
and enhance cellular migration through the activation of
the AKT pathway and metallopeptidases. Besides the re-
lationship between miR-221 and clinical stages, metasta-
sis and capsular infiltration, Gramantieri et al. [45]
reported that higher miR-221 levels were observed in
multifocal HCCs versus unifocal tumors; miR-221 was
also found to be corrected with tumor size[43] and cir-
rhosis [42]. Different from these reports, miR-221 ex-
pression in the current study was not correlated with
the number of tumor nodes, tumor diameter or cirrho-
sis. The number of samples involved and different methods
to detect miR-221 could partially explain the discrepancies.
Additionally, miR-221 level was neither related to other
clinical features, such as: age, gender, differentiation, AFP
level or portal vein tumor embolus.
Recently, some miRNAs were also identified in serum
and plasma in a remarkably stable form that is protected
from endogenous RNase activity [49,50]. Li et al. [51]
investigated the serum miR-221 expression in HCC.
Similarly to HCC tissues, miR-221 was found to be dif-
ferentially overexpressed in HCC serum samples, and
high level of miR-221 expression was correlated with
tumor size, cirrhosis and tumor stage. In addition,
Kaplan–Meier survival analysis showed that the overall
survival rate of the high miR-221 expression group (27.6%)
was significantly lower than that of the low miR-221
expression group. Thus serum miR-221 could act as a
noninvasive prognostic biomarker for HCC.
MiR-221 was also studied functionally in vitro and
in vivo. Pineau et al. [44] investigated the role of miR-221
Figure 10 Effect of miR-221 on apoptosis of HCC cells by
Hoechst 33342/propidium iodide (PI) double fluorescent
chromatin staining. HCC cells were treated the same as above in
Figure 5 and the apoptosis was monitored with Hoechst 33342/PI
double fluorescent chromatin staining. * P<0.05, ** P<0.01,
compared to blank control at the same time point.
Figure 11 Effect of miR-221 on caspase-3/7 activity of HCC
cells. HCC cells were treated the same as described in Figure 5 and
the caspase-3/7 activity was detected using Apo-ONE Homogeneous
Caspase-3/7 Assay. * P<0.05, ** P<0.01, compared to blank control at
the same time point.
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Figure 12 Effect of miR-221 on apoptosis of HCC HepB3 cells by flow cytometry. HCC HepB3 cells were treated with miR-221 inhibitor, mimic
and different controls for 96 hrs and the apoptosis was accessed with 7-Amino-actinomycin D (7-AAD) / APC Annexin V staining by flow cytometry.
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observed that most HCC cell lines, including HepG2 used
also in our study, formed larger colonies than controls.
When miR-221 antagomiR was transfected into HLE and
Malhavu cells, the cell growth was drastically inhibited.
Whereas, the same treatment led to no change in cell pro-
liferation in PLC/PRF5 and Huh6 cell lines. In the current
study, we transfected miR-221 inhibitor and mimic by
combiMAGnetofection into different HCC cell lines
(HepB3, HepG2 and SNU449). The cell growth was moni-
tored by three independent assays: CellTiter96 AQueous
One Solution Cell Proliferation Assay, CellTiter-Blue Cell
Viability Assay and Hoechst 33342/PI double fluorescent
chromatin staining. The results of the three methods were
in agreement with each other and enhanced the observa-
tion of Pineau et al. [44]. With miR-221 inhibitor, the cell
growth was inhibited in all the HCC cell lines tested. By
contract, with miR-221 mimic, the cell growth was moder-
ately accelerated in HepB3 and HepG2 cells. However, theeffect of miR-221 mimic to enhance the cell growth in
SNU449 cells was mild and without significantly diffe-
rence when compared to the negative controls. Cell cycle
was also detected by flow cytometry. When HepB3 cells
were transfected with miR-221 mimic post 96 hrs, a 1.8
fold increase in the S-phase cell population was observed,
which explained the character of miR-221 accelerating
HCC cell growth. Yuan et al. [52] reported that miR-221
enhances proliferation of in vitro cultivated primary hepa-
tocytes and adeno-associated virus mediated overexpres-
sion of miR-221 in the mouse liver also accelerates
hepatocyte proliferation in vivo. Furthermore, miR-221
overexpression leads to rapid S-phase entry of hepatocytes
during liver regeneration. These findings help explain the
mechanism of the relationship between miR-221 and
HCC cell proliferation. Fornari et al.[47] reported that
cyclin-dependent kinase inhibitor (CDKN) 1C/p57 and
CDKN1B/p27 are target genes of miR-221, and Yuan et al.
[52] reported that Aryl hydrocarbon nuclear translocator
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overexpression of miR-221 can promote cell cycle pro-
gression, by affecting both CDKN1C/p57, CDKN1B/p27
and Arnt proteins.
There were contradictory reports on the relationship be-
tween miR-221 and apoptosis in HCC. Dai et al. [53]
reported in HCC cells, endoplasmic reticulum (ER) stress-
induced apoptosis is enhanced by miR-221 mimic and atte-
nuated by miR-221 inhibitor. MiR-221 promoted-apoptosis
under ER stress is associated with p27(Kip1)- and MEK/
ERK-mediated cell cycle regulation. Thus, they concluded
that suppression of miR-221 plays a crucial role in the pro-
tection against apoptosis induced by ER stress in HCC cells.
On the contrary, Gramantieri et al. [37,45] found that the
apoptosis of HCC cell line SNU449 was induced with
knock-down of miR-221. Meanwhile, with a luciferase re-
porter assay, Bmf,a proapoptotic BH3-only protein [45],
and DNA damage-inducible transcript 4 (DDIT4) [44], a
modulator of the mTOR pathway, were confirmed to be
targets of miR-221. Moreover, the analysis of HCC tissues
revealed an inverse correlation between miR-221 and acti-
vated caspase-3, as a marker of apoptosis[45]. This explains
that miR-221 can inhibit apoptosis by targeting Bmf and
or/DDIT4. Furthermore, miR-221 has been identified as a
potent posttranscriptional regulator of FAS-induced apop-
tosis [54] and necrosis factor related apoptosis-inducing lig-
and related apoptosis [55]. In the current study, Hoechst
33342/PI double fluerenscent staining observed by micro-
scope and APC Annexin V/7-AAD staining by flow cyto-
metry were performed to test the effect of miR-221 on
apoptosis in HCC cells. The result of Gramantieri et al. [45]
could be repeated in the present study. More than that, we
also found that the apoptosis of HCC cell lines HepB3 and
HepG2 was significantly increased with miR-221 inhibitor.
However, miR-221 mimic did not succeed in reducing the
apoptosis even with the concentration of miR-221 increa-
sing to 300 nmol/L, suggesting that a saturation threshold
was reached in these cell lines by a single miRNA mimic.
To verify the data of apoptosis, we further detected the cas-
pase-3/7 activity. The result of caspase-3/7 activity was in
line with apoptosis. Hence, miR-221 could inhibit the apop-
tosis of HCC cells.
In vivo test has also been reported using the anti-miR-
221 oligonucleotides as a potential therapeutic for HCC
in mice [56]. Park et al. [56] showed that anti-miR-221
oligonucleotides could accumulate in the HCC tumors,
reduce endogenous miR-221 oligonucleotides, modulate
miR-221-related protein levels, and enhance the survival
of tumor-bearing mice.
Conclusions
Together with previous reports, the current observations
strongly confirm that miR-221 is an oncogenic miRNA
that plays a vital role in the initiation and progression ofhuman HCC, by affecting multiple pro-oncogenic path-
ways. MiR-221 expression in HCC FFPE or sera samples
could be a prognostic biomarker for HCC. On the other
hand, cell growth inhibition and apoptosis induction by
miR-221 inhibitor appears of great relevance due to its
possible therapeutic role. The use of synthetic inhibitor
of miR-221 might thus be a promising approach to HCC
therapies in the future.
Methods
Patients
This retrospective study included 76 cases of HCCs and
their corresponding paraneoplastic liver FFPE tissues. The
ages of HCC patients ranged from 29 to 81 years old, with
a mean of 52 years. A TNM classification (American Joint
Committee on Cancer (AJCC)/International Union Against
Cancer (UICC) staging system) was used to stratify HCC
patients’ clinical stages [57]. This classification considers
tumor size and number, vascular invasion, bilobar involve-
ment and extra-hepatic metastasis. Clinicopathological
information was obtained from medical records and sum-
marized in Table 1. The corresponding paraneoplastic tis-
sues were taken at least 2 cm from the cancerous node. All
cases were initial hepatectomies and randomly chosen
from the hepatectomies performed over a 1–2 year span in
the First Affiliated Hospital, Guangxi Medical University,
P.R. China between March 2010 and March 2011. Forty-
eight patients were followed up till 6th, July, 2012. Time-
to-recurrence was the time from randomization (operation
date) to the time of radiological recurrence [58]. Study
design was revised and approved by Guangxi Medical
University Ethical Committee. Written informed consent
to use the samples for research was obtained from the
patients and clinicians. All samples were independently
reviewed and diagnosed by two pathologists.
Cell culture
The human HCC-derived cell lines HepB3 (ATCC HB-
8064), HepG2 (ATCC HB-8065) and SNU449 (ATCC
CRL-2234) were purchased from the American Type
Culture Collection (ATCC, Rockville, MD,USA). HepB3
and HepG2 cell lines were cultured in Dulbecco’s modified
essential medium (DMEM, Invitrogen Corp., Grand Island,
NY, USA), whereas SNU449 was cultured with RPMI 1640.
Both media were supplemented with 10% heat-inactivated
fetal bovine serum (Invitrogen Corp., Grand Island, NY,
USA), 2 mM glutamine, gentamicin, but without antibio-
tics, at 37°C in a humidified incubator with 5% CO2. All
in vitro experiments were performed in triplicate.
RT-qPCR
For clinical FFPE tissues, blocks were sectioned at a
thickness of 10μm (3 sections for total RNA isolation).
The tissues were dewaxed by xylene and ethanol. The
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miRNeasy FFPE Kit (QIAGEN, KJ Venlo, Netherlands)
according to the manufacturer’s instructions with modi-
fications by changing the incubation time after mixing
with proteinase K to 36h at 55°C, meanwhile, adding
proteinase K every 12 hrs to maintain its concentration.
Depending on the size of the tumor sample, the RNA
concentration ranged from 20ng/μl to 2μg/μl detected
by Nanodrop 2000 (Wilmington, DE 19810 USA). Previ-
ously, we found the combination of RUN6B and let-7a
was the most stable internal reference for HCC in vitro
experiments by NormFinder and geNorm software,
whereas the combination of RUN6B and RUN48 was the
best housekeeping gene for HCC FFPE work (data not
shown). Thus, different internal references were used in the
current study. The primers for miR-221, RNU6B, RNU48
and let-7a were included in TaqManW MicroRNA Assays
(4427975–000468, Applied Biosystems, Life Technologies
Grand Island, NY 14072 USA). The reverse primers were
also used in the reverse transcription step with TaqManW
MicroRNA Reverse Transcription Kit (4366596, Applied
Biosystems, Life Technologies Grand Island, NY 14072
USA) in a total volume of 10 μl. For in vitro experiments,
the total Cellular RNA isolation was performed on the ABI
PRISM 6100 prepstation using the AbsoluteRNA Solution
(Applied Biosystems, Life Technologies Grand Island, NY
14072 USA) to remove contaminating DNA and PCR
inhibitory substances. Real-time qPCR for miRNA was
performed with Applied Biosystems PCR7900 [59-61]. The
miR-221 abundance in each sample was normalized to its
references. The miR-221 expression in FFPE experiment
was calculated with the formula 2-Δcq, and the change ratio
of miR-221 in the in vitro experiments was: (1-1/2ΔΔCq) ×
100% [62].
Re-expression and inhibition of miR-221 in HCC cells
HCC cells were seeded in a 24-well plate (2.5 × 104 cells
per well) or a 96-well plate (2.5 × 103 cells per well) and
incubated at 37°C for 24 hrs. The cells were then trans-
fected with miR-221 inhibitor, miRNA inhibitor negative
control, miR-221 mimic and miRNA mimic negative
control (Ambion, Life Technologies Grand Island, NY
14072 USA) at a final concentration of 200 nmol/L using
combiMAGnetofection (OZ BIOSCIENCES , Marseille
cedex 9 France ) in accordance with manufacturer's pro-
cedure. The cells were transfected with the miRNA
mimic or miRNA inhibitor daily up to 96 hrs. After
transfection, intermediate samples at 24, 48 and 72 hrs
were collected and analyzed by different assays.
Western blot analysis
After transfection with miR-221 inhibitor, miR-221
mimic and different controls, the cells were washed with
PBS and lysed in a buffer containing Tris/HCL (ph 7.6)20mM, NaCl 150mM (ph 6.85), EDTA 1mM (ph 8),
TRITON-X 1%, Na-pyrophosphate 2.5mM, Sodium
orthovanadate (Na3VO4) 1mM, Leupeptin 1μg/ml, pro-
tease inhibitor cocktails 1% and phosphotase inhibitor
cocktails 1% (Sigma-Aldrich N.V. St. Louis, USA). The
lysates were centrifuged at 12,000 × g for 10 min at 4°C
and boiled for 5 min. The protein concentration of the
lysate was detected by the Bio-Rad Bradford protein
assay and 25μg of denatured protein was subjected to
SDS-PAGE (10% SDS-acrylamide gel) with a loading
buffer containing 80mM Tris–HCl (ph 6.8), 5% SDS,10%
glycerol, 5mM EDTA (ph 8), 5% 2-Mercapto Ethanol,
0.2% Bromophenolblue and 1mM phenylmethylsulfonyl
fluoride The separated proteins were transferred to
PVDF membranes (BioRad) for 2 hrs at 100 mA. The
membrane was incubated with a p27 Kip1 (SX53G8.5)
Mouse Monoclonal Antibody (#3698), p57 Kip2 Rabbit
Polyclonal Antibody (#2557, 1:1000 dilution, Cell Signa-
ling Technology, Inc.3 Trask Lane, Danvers, MA 01923)
or a β-actin antibody (A1978 AC-15 1:2000 dilution,
Sigma-Aldrich N.V. St. Louis, USA). Primary antibodies
were detected with an HRP-conjugated secondary anti-
body (1:4000 dilution, ECL Anti-mouse or Anti-rabbit
IgG Peroxidse linked Na 931, Sigma-Aldrich N.V. St.
Louis, USA) and finally the membranes were subjected
to chemiluminescence detection assay. Experiments
were repeated in triplicate.Cell viability
Cell viability was assessed using a fluorimetric detection
of resorufin (CellTiter-Blue Cell Viability Assay,
G8080, Promega, Madison, USA). The protocol was
as follows: miR-221 inhibitor, miR-221 mimic and their
negative controls were transfected to 96 well plates and
incubated at 37°C for up to 96 hrs. The procedure was
according to the manufacturer. Fluorimetry (ex: 560 nm /
em: 590 nm) was using an FL600 fluorescence plate reader
(Bio-Tek, Virginia, USA). Fluorescence data are(or were)
expressed as the fluorescence of treated sample / mock
control ×100.Cell proliferation
To further confirm the data from the above cell viability
assay, cell proliferation was detected by a colorimetric tetra-
zolium (MTS) assay (CellTiter96 AQueous One Solution
Cell Proliferation Assay G3580, Promega, Madison, USA).
The treatments and controls were as mentioned above.
After transfections, addition of 20 μl of MTS reagent to
each well, the plates were incubated for 2 hrs at 37°C in a
humidified 5% CO2 atmosphere, and the absorbance at
490 nm was recorded using a 96-well microplate reader
(Scientific Multiskan MK3, Thermo Finland). The results
were the mean of six wells and expressed as the ratio of
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Fluorescent microscopy evaluation of cell apoptosis and
morphology
Besides the CellTiter-Blue cell viability assay and MTS
assay, cell growth was also monitored with Hoechst 33342
(Sigma-Aldrich N.V. St. Louis, USA) and propidium
iodide (PI, Sigma-Aldrich N.V. St. Louis, USA) double
fluorescent chromatin staining. With this assay, the effects
of miR-221 inhibitor and mimic on apoptosis and nuclear
morphology in the HCC cells could also be assessed. In
brief, after different transfections, cells were washed with
ice-cold PBS and stained 15min with Hoechst 33342
(1 mg/ml) and PI (1 mg/ml), and observed under an
advanced fluorescence microscope (ZEISS Axiovert 25,
Munich, Germany). Apoptosis and nuclear morphology
were identified by condensation of nuclear chromatin and
its fragmentation. This system determines the absolute
number of viable cells (Hoechst 33342 positive/PI
negative), early apoptotic cells (Hoechst 33342 positive/PI
negative with blue fragmentations in the cells), late
apoptotic cells (Hoechst 33342 positive/PI positive, with
red fragmentations in the cells), necrotic cells (PI positive)
and debris signals. Viable, apoptotic and necrotic cells were
counted in 10 different fields under the 200× vision in each
well in three independent experiments by two persons and
the average result was compared to the mock control.
Apoptotic cell numbers from different treatments
were compared by being normalized to their viable
cell numbers [61].
Flow cytometry analysis of cell cycle
HepB3 cells (1×105) were selected to test the effect of
miR-221 on cell cycle. Cells were plated into 6-well
culture plates and treated with miR-221 inhibitor, mimic
and their negative controls for 96h. Cells were collected
with trypsin, then washed once with 4°C PBS, and fixed
in cold 75% ethanol at 4°C. Cells were then washed once
again with 4°C PBS and re-suspended with PBS, then
stained with 50 mg/ml PI and 100 mg/ml RNase A
solution (Genview, Carlsbad, CA) for 20 min at 37°C in
dark. Stained cells were subjected to analysis immediately
by flow cytometry. The proportion of cells in each phase
of the cell cycle was determined by a BDFACScan for
Quantitative Cell Analysis.
Caspase-3/7 activity detection
Caspase-3/7 activity was measured using a synthetic
rhodamine labeled caspase-3/7 substrate (Apo-ONEW
Homogeneous Caspase-3/7 Assay, G7790, Promega,
Madison, USA) performed immediately after the detection
of cell viability (described above) on the same wells,
according to the instructions of the manufacturer. Afterincubation at room temperature for 60min, the fluor-
escence of each well was measured (ex: 499 nm / em:
512 nm), using a FL600 fluorescence plate reader.
Caspase-3/7 activity is expressed as fluorescence of treated
sample / mock control×100.Flow cytometry analysis of apoptosis
HepB3 cells (1×105) were also selected further to confirm
the effect of miR-221 on apoptosis, using 7-Amino-
Actinomycin (7-AAD)/APC Annexin V (BD Pharmingen™,
South San Francisco, CA, USA) with flow cytometry. Cells
were prepared as above and the procedure was according
to the manufacturer. This assay allows to identify early
apoptotic cells (7-AAD negative, APC Annexin V positive)
and late apoptosis or already dead (both APC Annexin V
and 7-AAD positive).Statistical analysis
SPSS19.0 (Munich, Germany) was used for statistical ana-
lysis. Results were representative of three independent
experiments unless stated otherwise. Values were presented
as the mean ± standard deviation (SD). One-way Analysis
of Variance (ANOVA) test and Student’s paired t-test were
used to analyze significance between groups. The Least
Significant Difference (LSD) method of multiple compa-
risons with parental and control group was applied when
the probability for ANOVA was statistically significant.
Statistical significance was determined at a P<0.05 level.
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